ONEGLOBALOne Global Service Provider Limited
Pharma · Pharmaceutical Retailers · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
One Global Service Provider Limited engages in the provision of healthcare services worldwide. The company offers diagnostic services, including anemia, antenatal, diabetes, diabetes monitoring, hypertension, kidney, and lipid profiles, as well as liver function tests; and healthcare services, such as end-to-end solutions in industrial occupational check-ups, population screening for non-communicable diseases, disease surveillance programs, electronic medical records and health registry, health analytics for predictive and preventive actions, and wellness programs for lifestyle diseases. It also provides laboratory services, such as biochemistry, microbiology, hematology and coagulation, histopathology and cytopathology, clinical pathology, molecular diagnostics, and serology. In addition, the company offers healthcare products, such as medical devices, equipment, medical consumables, and reagents through an online platform; and healthcare solutions comprising home-based health screening, public health data analytics, and home-based remote care services. Further, it is involved in the consultancy and development, requirements, designing, developing, testing, integrating, deploying, and maintaining of software/IT products; and purchasing, sale, distribution of licenses, resale, import, export of IT and software products. The company was formerly known as Overseas Synthetics Limited. One Global Service Provider Limited was incorporated in 1992 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ONEGLOBAL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Risk gate: safety score is only 19/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Dividend yield: 0.23%
- • RSI: 34
- • MACD: bearish
- • 1-month return: -27.2%
Bull case
- • Revenue growth: 17.0% YoY
- • Profit growth: 45.8% YoY
- • ROE: 49.2%
- • Trend strength (ADX): 29
Bear case
- • Dividend yield: 0.23%
- • RSI: 34
- • MACD: bearish
- • 1-month return: -27.2%
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Dividend yield: 0.23%
- • RSI: 34
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹41.76). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.